drugset / Trial / NCT04052620

Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study

NCT04052620 ↗

Phase 3 Completed 313 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of diclofenac diethylamine 2.32 percent (%) gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily for 7 days in participants with acute ankle sprain.

Timeline

Start
2019-10-24
Primary completion
2020-11-12
Completion
2020-11-12

Outcome

Met primary endpoint

paper the upper limit (5.22 mm) of the 95% CI was less than the noninferiority margin of 13 mm PMID 36566202 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac diethylamine Unknown 1.16 % Topical
Subject Diclofenac diethylamine Unknown 2.32 % Topical

Indications

No indication recorded.